| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGa2B |
| Uniprot No | P08514 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 639-887aa |
| 氨基酸序列 | CVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKR |
| 预测分子量 | 33.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGA2B重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：Expression and functional characterization of recombinant integrin αIIbβ3 in mammalian cells
**作者**：Li R et al.
**摘要**：该研究在CHO细胞中成功表达了重组人αIIbβ3整合素复合体，证实其能结合纤维蛋白原并介导血小板样细胞黏附，为研究抗血小板药物提供了体外模型。
2. **文献名称**：Structural basis of integrin αIIbβ3 activation by pathogenic mutations in the β3 knee region
**作者**：Zhu J et al.
**摘要**：通过冷冻电镜解析了β3亚基膝部突变体(如D723H)导致的重组αIIbβ3组成性激活的分子机制，揭示了突变引发构象变化进而促进血栓形成的结构基础。
3. **文献名称**：Recombinant αIIbβ3 integrin fragments as inhibitors of platelet aggregation in Glanzmann thrombasthenia therapy
**作者**：Nurden AT et al.
**摘要**：研究构建了截短型重组αIIbβ3蛋白片段，证实其可竞争性抑制病理性血小板聚集，为Glanzmann血小板无力症的基因治疗提供了新型生物制剂候选。
(注：文献为虚拟示例，实际引用需检索PubMed/Google Scholar等数据库获取真实文献信息。)
**Background of ITGA2B Recombinant Protein**
ITGA2B (Integrin Alpha-2B), also known as CD41. is a critical subunit of the heterodimeric integrin αIIbβ3 receptor, predominantly expressed on platelets and megakaryocytes. This transmembrane glycoprotein plays a pivotal role in platelet aggregation and adhesion during hemostasis and thrombosis. The αIIbβ3 integrin binds ligands such as fibrinogen, von Willebrand factor (vWF), and fibronectin, facilitating cross-linking of platelets at injury sites. Dysregulation of ITGA2B/β3 function is linked to bleeding disorders (e.g., Glanzmann thrombasthenia) or thrombotic diseases.
Recombinant ITGA2B protein is engineered *in vitro* using expression systems like mammalian cells (e.g., HEK293) or bacteria to produce soluble, functional forms for research and therapeutic applications. Its production often involves co-expression with the β3 subunit (ITGB3) to maintain structural integrity and ligand-binding activity. Purification typically employs affinity tags (e.g., His-tag) for high yield and purity.
In research, recombinant ITGA2B enables mechanistic studies of platelet activation, thrombosis pathways, and drug discovery. It serves as a tool to screen antiplatelet agents (e.g., antagonists like abciximab) targeting αIIbβ3 to prevent pathological clot formation. Additionally, it aids in diagnosing autoimmune disorders involving anti-αIIbβ3 antibodies.
Therapeutically, recombinant ITGA2B derivatives are explored for gene therapy in Glanzmann thrombasthenia or as components of platelet-mimicking nanoparticles for targeted drug delivery. Advances in protein engineering, such as stabilizing conformational states (active vs. inactive), further enhance its utility in mimicking physiological or pathological conditions.
Overall, ITGA2B recombinant protein bridges basic science and clinical innovation, offering insights into hematological diseases and paving the way for novel diagnostics and therapies.
×
